Accelrys Announces Purchase of Cloud-based HEOS Drug Discovery Information Management Technology from SCYNEXIS Robust SaaS workspace accelerates and streamlines collaborative drug discovery for virtual teams
SAN DIEGO, May 17, 2012 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, today announced that it has purchased the Web-based Hit Explorer Operating System (HEOS) from SCYNEXIS, Inc. The HEOS purchase is the final phase of a strategic agreement that began in 2011, which enabled Accelrys to market and sell HEOS as a key offering within Accelrys' market-leading Cheminformatics Suite of software applications. HEOS enables more efficient and streamlined drug discovery collaborations, particularly for organizations leveraging academic departments, research institutes and contract research organizations (CROs) in externalized R&D projects.
Enabled by Accelrys applications, HEOS is a proven Software-as-a-Service (SaaS) workspace that accelerates and streamlines collaborative drug discovery by providing secure, real-time access to chemical registration, biological assay results, computational and visual analytics, safety assessment and pharmacokinetics data, and other project information in the Cloud with minimal IT overhead and effort.
"HEOS supports an important new operating model for collaborating organizations that require secure, flexible information management and collaboration with global reach," said Accelrys President and Chief Executive Officer Max Carnecchia. "As many of our customers move to multi-site, multi-collaborator projects to accelerate innovation and reduce costs, we look forward to broadening the applicability and reach of HEOS as a secure, easy-to-use, Cloud-based information management workspace for the wider scientific community."
HEOS has already securely captured hundreds of thousands of compounds and millions of assay test results in a broad range of global pharmaceutical and biotechnology programs ranging from early discovery to preclinical projects. A worldwide network of organizations is currently using the system to capture, consolidate and harmonize data used in the study of neglected diseases.
Accelrys' purchase of the HEOS SaaS-based system includes software and supporting personnel.
To learn more about HEOS, watch the on-demand introductory webinar "Introducing HEOS – A Cloud-based Collaborative Drug Discovery Workspace."
About Accelrys, Inc.
Accelrys (NASDAQ: ACCL), a leading scientific enterprise R&D software and services company, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.
Accelrys solutions are used by more than1,300 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.
Michael A. Piraino
Executive Vice President &
Chief Financial Officer
Marla Kertzman, 415-694-6701
SOURCE Accelrys, Inc.